Berlin, Germany, March 19, 2014 --(PR.com
)-- The Berlin-based clinical research alliance, Medis Research Group, has added a further asset to its portfolio. By welcoming OnkoDataMed GmbH among their midst, the group is quickly growing into a premium provider of Oncology clinical trial solutions. So far, Medis Research Group, founded in November 2013, consisted of its two founding members, Allied Clinical Management and ICRC-Weyer, both Berlin-based contract research organizations, each with its own portfolio of highly specialized services. The group was formed in a move to better meet requirements of clinical trial sponsors for one-stop shop solutions, hence enabling the two CROs to combine clinical research expertise and to provide complete service solutions across all stages of the clinical development process. The group has now added the expertise and the network of Oncology trial sites of Berlin-Brandenburg-based OnkoDataMed GmbH.
OnkoDataMed is a specialist provider of remote data capture solutions within a network of dermatologic, urologic and gynecologic oncologists. Through this network, Medis Research Group has now access to one of the largest epidemiological and clinical oncology databases in Europe containing information on thousands of patients currently in treatment – a valuable source for retrospective data analysis.
Dr Lutz Reimer, Managing Director of OnkoDataMed, says: "We are very happy to be joining Medis Research Group as one of the core members. The group’s clinical research services complement the portfolio of OnkoDataMed enabling us to jointly provide a wide range of services for the conduct of entire trial projects and retrospective data analysis. On the other hand, we can contribute to the group with our proven remote data capture software ODM QuaSi® as well as our large database of Urologic and Gynecologic Oncology patients."
Michael Roehl, Managing Director of Allied Clinical Management, acknowledges: "We are very pleased to have OnkoDataMed on board with us. Having access to hundreds of thousands of comprehensively documented oncology therapy cycles forms the basis for retrospective and prospective longitudinal studies which we can use to guide the market launch of a sponsor’s new product."
Prof Dr Geerd Weyer, Founder and Managing Director of ICRC-Weyer, adds: "We can further perform cross-analyses of data parameters drawn from our network of oncology practices in Germany. As of January 2014, this network comprises over 220,000 patients undergoing hormone therapy for prostate carcinomas, over 135,000 Gynecologic Oncology patients as well as over 10,000 Uro-Oncology patients undergoing chemotherapy per year."
Apart from the network of over 500 experienced dermatologic, urologic and gynecologic oncology practices in Germany, Medis Research Group has been performing site management and monitoring of phase Ib to III trials in over 20 leading university clinics specializing in colorectal, breast and pancreatic cancers in Germany, Austria and Switzerland, making the group a leading provider of clinical research services for prospective clinical trials, non-interventional and retrospective studies throughout the DACH region.
Medis Research Group will – for the first time in this constellation – introduce its consolidated services portfolio at the ICPM / DGPharMed Annual Conference in Berlin, 20-21 March 2014 as well as the DIA 26th Annual Euromeeting in Vienna, 25-27 March 2014. The group will be represented with a booth at each of these events.
About Medis Research Group:
Medis Research Group is a strategic partnership of three Berlin-Brandenburg based clinical research organizations: ICRC-Weyer, OnkoDataMed and Allied Clinical Management. The group provides complete solutions for the conduct of phase I to IV trials as well as retrospective studies. The solutions include study setup and conduct, eCRF design, data handling, analysis and reporting as well as all aspects of drug safety.